Palisade Bio Provides Update on Advancement of its Strategic Collaboration with Strand Life Sciences
21 Junho 2024 - 9:15AM
Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”
or the “Company”), a biopharmaceutical company focused on
developing and advancing novel therapeutics for patients living
with autoimmune, inflammatory, and fibrotic diseases, today
provided an update on key areas of progress for its previously
announced strategic collaboration with Strand Life Sciences
("Strand"), a leading bioinformatics specialist, aimed at advancing
precision medicine for ulcerative colitis (UC) therapy.
Under the collaboration through an extensive
analysis of transcriptomics datasets and clinical biomarkers,
Palisade Bio and Strand have identified promising PDE4-related
biomarkers associated with UC pathology, providing valuable
insights for targeted therapeutic interventions.
Key areas of progress include:
Candidate Predictive Biomarker
Identification:
- Candidate
PDE4-related biomarkers overlapping with UC pathophysiology have
been identified, paving the way for the development of innovative
precision medicine approaches for treatment of UC patients with
PDE4-inhibitors.
Patient Stratification:
- Ongoing research
focuses on refining patient selection strategies based on
PDE4-related biomarkers and disease characteristics to optimize
clinical outcomes for patients with UC.
Pipeline Development:
- Progress has been made in refining
Palisade’s precision medicine approach, integrating clinical
biomarkers, disease activity measures, and transcriptomics data, to
tailor personalized UC therapies.
Dr. Mitch Jones, CMO at Palisade Bio stated, “We
remain committed to advancing precision medicine solutions for UC
and other inflammatory indications. Collaborative efforts with
Strand and other partners will continue to drive innovation and
transform the landscape of UC treatment.”
“Looking ahead, as we pioneer innovative
precision medicine approaches, Palisade aims to become a leader in
developing precision medicine solutions within inflammatory and
fibrotic indications, creating value for investors and helping
patients,” added JD Finley, Palisade Bio’s CEO.
About Palisade Bio
Palisade Bio is a biopharmaceutical company
focused on developing and advancing novel therapeutics for patients
living with autoimmune, inflammatory, and fibrotic diseases. The
Company believes that by using a targeted approach with its novel
therapeutics it will transform the treatment landscape. For more
information, please go to www.palisadebio.com.
Forward Looking Statements
This communication contains “forward-looking”
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements regarding the Company’s intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the extent of our cash runway; our
ability to successfully develop our licensed technologies;
estimates about the size and growth potential of the markets for
our product candidates, and our ability to serve those markets,
including any potential revenue generated; future regulatory,
judicial, and legislative changes or developments in the United
States (U.S.) and foreign countries and the impact of these
changes; our ability to maintain the Nasdaq listing of our
securities; our ability to build a commercial infrastructure in the
U.S. and other markets; our ability to compete effectively in a
competitive industry; our ability to identify and qualify
manufacturers to provide API and manufacture drug product; our
ability to enter into commercial supply agreements; the success of
competing technologies that are or may become available; our
ability to attract and retain key scientific or management
personnel; the accuracy of our estimates regarding expenses, future
revenues, capital requirements and needs for additional financing;
our ability to obtain funding for our operations; our ability to
attract collaborators and strategic partnerships; and the impact of
the COVID-19 pandemic or any global event on our business, and
operations, and supply. Any statements contained in this
communication that are not statements of historical fact may be
deemed to be forward-looking statements. These forward-looking
statements are based upon the Company’s current expectations.
Forward-looking statements involve risks and uncertainties. The
Company’s actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of these risks and uncertainties, which
include, without limitation, the Company’s ability to advance its
nonclinical and clinical programs, the uncertain and time-consuming
regulatory approval process; and the Company’s ability to secure
additional financing to fund future operations and development of
its product candidates. Additional risks and uncertainties can be
found in the Company’s Annual Report on Form 10-K for the fiscal
year ended December 31, 2023 and Quarterly Report on Form 10-Q,
filed with the Securities and Exchange Commission (“SEC”) on March
26, 2024 and May 13, 2024, respectively. These forward-looking
statements speak only as of the date hereof and the Company
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein to reflect any change in the Company’s
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are
based.
Investor Relations ContactJTC
Team, LLCJenene Thomas 833-475-8247PALI@jtcir.com
Palisade Bio (NASDAQ:PALI)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Palisade Bio (NASDAQ:PALI)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024